Impact of Bacille Calmette-Guérin revaccination on serum IgE levels in a randomized controlled trial
- Resource Type
- Authors
- Francisco Soares Nascimento-Sampaio; Evelin Santos Oliveira; Elisabete Lopes Conceição; Thaís Silva Peleteiro; Neuza Maria Alcântara-Neves; Theolis Costa Barbosa Bessa; Carlos Maurício Cardeal Mendes
- Source
- Revista da Sociedade Brasileira de Medicina Tropical, Volume: 51, Issue: 1, Pages: 94-98, Published: FEB 2018
Revista da Sociedade Brasileira de Medicina Tropical, Vol 51, Iss 1, Pp 94-98
- Subject
- 0301 basic medicine
Microbiology (medical)
Male
Allergy
lcsh:Arctic medicine. Tropical medicine
Time Factors
Adolescent
lcsh:RC955-962
Immunization, Secondary
Down-Regulation
Immunoglobulin E
law.invention
Atopy
03 medical and health sciences
Interferon-gamma
Young Adult
0302 clinical medicine
Randomized controlled trial
law
medicine
Hypersensitivity
Humans
Young adult
Respiratory system
Skin Tests
biology
business.industry
Tuberculosis vaccine
medicine.disease
030104 developmental biology
Infectious Diseases
030228 respiratory system
Immunology
biology.protein
BCG Vaccine
Parasitology
Female
Tuberculosis vaccines
business
BCG vaccine
- Language
- ISSN
- 1678-9849
INTRODUCTION: Bacille Calmette-Guérin (BCG) downmodulates allergen-specific IgE levels and prevents other atopic responses in experimental models but fails to protect against respiratory allergies. Human responsiveness to BCG is variable and may interfere with protection. METHODS: Multivariate models were evaluated to test the possible effect of responsiveness (assessed by IFN-γ production) to BCG revaccination on the modulation of total and allergen-specific serum IgE levels in healthy volunteers participating in a randomized controlled trial. RESULTS: Serum total or Derp-specific IgE levels did not change regardless of the increase in IFN-γ levels. CONCLUSIONS: BCG responsiveness does not affect protection against atopy.